Skip to content

Evaluation of Sleep Changes in Inflammatory Bowel Diseases (IBD) Patients.

Evaluation of Sleep Changes as Early Markers of Relapse in Patients With Inflammatory Bowel Diseases (IBD).

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05835973
Acronym
RECIDREAM
Enrollment
216
Registered
2023-04-28
Start date
2025-04-08
Completion date
2028-06-08
Last updated
2025-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn Disease, Disease Bowel, Ulcerative Colitis

Keywords

Inflammatory Bowel Diseases, Crohn's disease, ulcerative colitis, sleep deprivation, relapse

Brief summary

Inflammatory Bowel Diseases (IBD) go through two phases: flare and remission. Prediction of flares and identification of patients in remission but at high risk of flare are a major issue when taking care of IBD patients. Considering close interactions between sleep, immunity and intestinal inflammation, sleep disorders could be a predictor of flares. The purpose of this study is to demonstrate that sleep efficacy decreases before IBD flare. Patients in remission will be assessed for IBD symptoms (activity scores, biological factors) and sleep disorders (actigraphy, DREEM®, questionnaires) during one year.

Interventions

OTHERSleep activity

Actinography : Patient will wear actinometers on the wrist for 1 year continuously. In the study, MotionWatch 8 actimeters will be used, a class 1 medical device with CE mark (EN ISO 13485:2016 standard). Ancillary study : DREEM 3 headband : a subgroup of patients will wear the headband during 2 nights every 3 months.

OTHERQuestionnaires

The PSQI, EPWORTH, FACIT-F, ISI, and ICSD-3 questionnaires will be completed by patients every 3 months during their follow-up consultation according to the usual management. The questionnaire by Horne and Ostberg will be completed by the patients only during the inclusion visit.

Sponsors

Hospices Civils de Lyon
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Patient over 18 and under 65 years of age. * Patient with Inflammatory Bowel Disease diagnosed for at least 3 months. * Patient in remission, for at least 3 months: 1. clinical remission: Harvey-Bradshaw score (HBI) \< 5 for CD and a Mayo score \< 3 for UC 2. and biological remission: absence of objective inflammation defined by CRP \< 5 mg/L and/or fecal calprotectin \< 250 µg/g. * Patient must sign informed consent form to participate to the study. * Patient affiliated to or benefiting from a social security plan.

Exclusion criteria

* Patient with complications (obstructive symptoms, fistulas or intra-abdominal abscesses in the previous three months). * Patient with extensive bowel resection (\> 40 cm of small bowel). * Patient with an ileostomy or colostomy. * Patient diagnosed with sleep disorders. * Patient without legal capacity to consent. * Pregnant, parturient or nursing women. * Persons deprived of liberty by judicial or administrative decision. * Persons under psychiatric care. * Persons admitted to a health or social institution for purposes other than research. * Persons of full age who are subject to a legal protection measure (guardianship, curators).

Design outcomes

Primary

MeasureTime frameDescription
rate of relapse12 months after baselineFor Crohn's disease: Harvey Bradshaw Index ≥ 5 AND a CRP \> 5 mg/L and/or calprotectin \> 250 µg/g For ulcerative colitis: Mayo ≥ 3 AND a CRP \> 5 mg/L and/or calprotectin \> 250 µg/g Sleep efficiency will be measured by actimetry and expressed as a percentage. Sleep efficiency is defined as the ratio of total time spent asleep compared to total time spent in bed. An actinometer will collect one efficiency measurement per night; an average per week will then be calculated from the daily measurements.

Secondary

MeasureTime frameDescription
Intra-sleep wakefulness duration (min), sleep latency (min) and sleep duration (min)12 months after baselineIntra-sleep wakefulness duration (min), sleep latency (min) and sleep duration (min) will be measured with an actinometer, and averaged per week. Patient will wear actinometers on the wrist for 1 year continuously.
total sleep time12 months after baselineSleep parameters evaluated by headband are: * sleep macrostructure: concerns the polycyclic organization of sleep and the following quantitative parameters: total sleep time (min), sleep onset latency (min), intra-sleep wake duration (min), polysomnographic sleep efficiency (= total sleep time/time in bed), quantity of different sleep stages (min and % of total sleep time) * sleep microstructure: concerns the index of micro-arousals (number/hour) and spindle density (number/minute) or delta spectral power in slow wave sleep (delta/total power ratio).
sleep onset latency12 months after baselineSleep parameters evaluated by headband are: * sleep macrostructure: concerns the polycyclic organization of sleep and the following quantitative parameters: total sleep time (min), sleep onset latency (min), intra-sleep wake duration (min), polysomnographic sleep efficiency (= total sleep time/time in bed), quantity of different sleep stages (min and % of total sleep time) * sleep microstructure: concerns the index of micro-arousals (number/hour) and spindle density (number/minute) or delta spectral power in slow wave sleep (delta/total power ratio).
intra-sleep wake duration12 months after baselineSleep parameters evaluated by headband are: * sleep macrostructure: concerns the polycyclic organization of sleep and the following quantitative parameters: total sleep time (min), sleep onset latency (min), intra-sleep wake duration (min), polysomnographic sleep efficiency (= total sleep time/time in bed), quantity of different sleep stages (min and % of total sleep time) * sleep microstructure: concerns the index of micro-arousals (number/hour) and spindle density (number/minute) or delta spectral power in slow wave sleep (delta/total power ratio).
Sleep efficiency calculated by actimetry and expressed in percentage.12 months after baselinePatient will wear actimeters on the wrist for 1 year continuously.
quantity of different sleep stages12 months after baselineSleep parameters evaluated by headband are: * sleep macrostructure: concerns the polycyclic organization of sleep and the following quantitative parameters: total sleep time (min), sleep onset latency (min), intra-sleep wake duration (min), polysomnographic sleep efficiency (= total sleep time/time in bed), quantity of different sleep stages (min and % of total sleep time) * sleep microstructure: concerns the index of micro-arousals (number/hour) and spindle density (number/minute) or delta spectral power in slow wave sleep (delta/total power ratio).
index of micro-arousals12 months after baselineSleep parameters evaluated by headband are: * sleep macrostructure: concerns the polycyclic organization of sleep and the following quantitative parameters: total sleep time (min), sleep onset latency (min), intra-sleep wake duration (min), polysomnographic sleep efficiency (= total sleep time/time in bed), quantity of different sleep stages (min and % of total sleep time) * sleep microstructure: concerns the index of micro-arousals (number/hour) and spindle density (number/minute) or delta spectral power in slow wave sleep (delta/total power ratio).
spindle density12 months after baselineSleep parameters evaluated by headband are: * sleep macrostructure: concerns the polycyclic organization of sleep and the following quantitative parameters: total sleep time (min), sleep onset latency (min), intra-sleep wake duration (min), polysomnographic sleep efficiency (= total sleep time/time in bed), quantity of different sleep stages (min and % of total sleep time) * sleep microstructure: concerns the index of micro-arousals (number/hour) and spindle density (number/minute) or delta spectral power in slow wave sleep (delta/total power ratio).
delta spectral power in slow wave sleep12 months after baselineSleep parameters evaluated by headband are: * sleep macrostructure: concerns the polycyclic organization of sleep and the following quantitative parameters: total sleep time (min), sleep onset latency (min), intra-sleep wake duration (min), polysomnographic sleep efficiency (= total sleep time/time in bed), quantity of different sleep stages (min and % of total sleep time) * sleep microstructure: concerns the index of micro-arousals (number/hour) and spindle density (number/minute) or delta spectral power in slow wave sleep (delta/total power ratio).
polysomnographic sleep efficiency12 months after baselineSleep parameters evaluated by headband are: * sleep macrostructure: concerns the polycyclic organization of sleep and the following quantitative parameters: total sleep time (min), sleep onset latency (min), intra-sleep wake duration (min), polysomnographic sleep efficiency (= total sleep time/time in bed), quantity of different sleep stages (min and % of total sleep time) * sleep microstructure: concerns the index of micro-arousals (number/hour) and spindle density (number/minute) or delta spectral power in slow wave sleep (delta/total power ratio).

Countries

France

Contacts

Primary ContactGilles Boschetti, MD,PhD
gilles.boschetti@chu-lyon.fr+33 4 78 86 13 02
Backup ContactMaelys Cheviakoff
maelys.cheviakoff01@chu-lyon.fr+33 4 78 86 37 66

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026